- 1 Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced
- 2 immunity from seasonal human coronavirus humoral responses
- 4 Eric D. Laing^{1*}, Spencer L. Sterling^{1,2}, Stephanie A. Richard^{2,3}, Nusrat J. Epsi^{2,3}, Si'Ana
- 5 Coggins^{1,2}, Emily C. Samuels^{1,2}, Shreshta Phogat^{1,2}, Lianying Yan^{1,2}, Nicole Moreno^{2,3}, Christian
- 6 L. Coles^{2,3}, Matthew Drew⁴, Jennifer Mehalko⁴, Caroline E. English^{2,3}, Scott Merritt^{2,3,5}, Katrin
- 7 Mende^{2,3,5}, Vincent J. Munster⁶, Emmie de Wit⁶, Kevin K. Chung⁷, Eugene V. Millar^{2,3}, David R.
- 8 Tribble³, Mark P. Simons^{1,3}, Simon D. Pollett^{2,3}, Brian K. Agan^{2,3}, Dominic Esposito⁴, Charlotte
- 9 Lanteri², G. Travis Clifton⁵, Edward Mitre¹, Timothy H. Burgess², and Christopher C. Broder^{1*}
- 12 ¹Department of Microbiology and Immunology, Uniformed Services University of the Health
- 13 Sciences, Bethesda, MD, USA
- 14 ²Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD
- 15 USA

10 11

- 16 ³Infectious Disease Clinical Research Program, Department of Preventive Medicine and
- 17 Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
- 18 ⁴Protein Expression Laboratory, National Cancer Institute RAS Initiative, Frederick National
- 19 Laboratory for Cancer Research, Frederick, MD, USA
- 20 ⁵Brooke Army Medical Center, JBSA Fort Sam Houston, TX, USA
- 21 ⁶Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and
- 22 Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
- ⁷Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD,
- 24 USA

25 26

27

41

- 28 *Correspondence
- 29 Eric D. Laing, PhD
- 30 Department of Microbiology and Immunology
- 31 Uniformed Services University, Bethesda, MD 20814
- 32 Phone: 301-295-9884
- 33 Fax: 301-295-1545
- 34 Email: eric.laing@usuhs.edu
- 35 Christopher C. Broder, PhD
- 36 Department of Microbiology and Immunology
- 37 Uniformed Services University, Bethesda, MD 20814
- 38 Phone: 301-295-3401
- 39 Fax: 301-295-1545
- 40 Email: christopher.broder@usuhs.edu

ABSTRACT

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Sensitive and specific SARS-CoV-2 antibody assays remain critical for community and hospitalbased SARS-CoV-2 sero-surveillance. With the rollout of SARS-CoV-2 vaccines, such assays must be able to distinguish vaccine from natural immunity to SARS-CoV-2 and related human coronaviruses. Here, we developed and implemented multiplex microsphere-based immunoassay strategies for COVD-19 antibody studies that incorporates spike protein trimers of SARS-CoV-2 and the endemic seasonal human coronaviruses (HCoV), enabling high throughout measurement of pre-existing cross-reactive antibodies. We varied SARS-CoV-2 antigen compositions within the multiplex assay, allowing direct comparisons of the effects of spike protein, receptor-binding domain protein (RBD) and nucleocapsid protein (NP) based SARS-CoV-2 antibody detection. Multiplex immunoassay performance characteristics are antigen-dependent, and sensitivities and specificities range 92-99% and 94-100%, respectively, for human subject samples collected as early as 7-10 days from symptom onset. SARS-CoV-2 spike and RBD had a strong correlative relationship for the detection of IgG. Correlation between detectable IgG reactive with spike and NP also had strong relationship, however, several PCR-positive and spike IqG-positive serum samples were NP IqG-negative. This spike and NP multiplex immunoassay has the potential to be useful for differentiation between vaccination and natural infection induced antibody responses. We also assessed the induction of de novo SARS-CoV-2 IgG cross reactions with SARS-CoV and MERS-CoV spike proteins. Furthermore, multiplex immunoassays that incorporate spike proteins of SARS-CoV-2 and HCoVs will permit investigations into the influence of HCoV antibodies on COVID-19 clinical outcomes and SARS-CoV-2 antibody durability.

INTRODUCTION

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel zoonotic positive-sense, single-stranded, RNA virus responsible for the third viral pandemic of the 21st century, and the third zoonotic coronavirus outbreak in the past 20 years (1, 2). At this time, SARS-CoV-2 has globally caused 106 million COVID-19 cases and over 2 million COVID-19 related deaths. Serology studies have demonstrated SARS-CoV-2 infection elicits an antibody responses that can persist for as long as 8 months (3), and that the magnitude of the antibody response is associated with COVID-19 severity (4, 5). A variety of antibody tests have been developed and granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (6), with the majority of these tests designed to assess for antibodies against the SARS-CoV-2 spike (S) envelope glycoprotein, the primary target of virus-neutralizing antibodies (7), in either its native-like oligomer conformation, or against one of its protein subunits or domains. A native-like SARS-CoV-2 prefusion stabilized S-2P glycoprotein ectodomain trimer (hereafter referred to as spike) (8, 9) has been adopted for large-scale SARS-CoV-2 antigenbased serology and serosurveillance (10-13). The receptor-binding domain (RBD) located within the more variable S1 subunit of the S glycoprotein, lacking potentially conserved epitopes with endemic seasonal human coronavirus (HCoV) S glycoproteins and conferring specificity for SARS-CoV-2, has also been extensively used in antigen-based immunoassays (10, 14-16). Furthermore, immunoassay detection of IgG antibodies that can bind to RBD has been used as a surrogate for neutralization tests which require cell-culture, pseudoviruses, or high biosafetycontainment and wild-type SARS-CoV-2 (15, 17, 18). Lastly, the SARS-CoV-2 nucleocapsid protein (NP) has been used in several lateral flow and antigen-based COVID-19 serology tests (6). A handful of microsphere-based SARS-CoV-2 serology assays have been developed, facilitating high throughput multiplex strategies for antibody detection (19-23). Multiplex

microsphere-based immunoassays (MMIA) have several advantages over traditional immunoassays including optical improvements in sensitivity and specificity, as well as reductions in sample volume and materials to test for antigen-specific antibodies since multiple target antibodies can be simultaneously captured with multiple antigens coupled to unique fluorescent microspheres. Additionally, multiplexing systems, e.g. Luminex xMAP-based platforms, have a large dynamic range, which have been shown to be more sensitive than ELISA for the detection of antibodies to viral infections (21, 24-26). As COVID-19 vaccine rollouts continue in the U.S., MMIA strategies allowing simultaneous detection of spike and NP reactive antibodies may facilitate differentiation of SARS-CoV-2 natural infection and vaccination (27), as all current U.S. FDA EUA COVID-19 vaccines induce humoral responses to the S glycoprotein (28, 29).

We have previously utilized a SARS-CoV-2 MMIA in cross-sectional serological analysis of military healthcare workers deployed to the Jacob K. Javits Center COVID-19 field hospital, (Javits Medical Station) (30) and U.S. Navy personnel deployed on the USNS COMFORT (31) and during the first SARS-CoV-2 epidemic wave in New York City, NY. Utilizing sera from three cohorts, a) SARS-CoV-2 naïve serum samples from the Acute Respiratory Infection Consortium Natural History Study (ARIC) collected from 2012 – 2018 (32), b) serum samples from PCR-confirmed SARS-CoV-2 subjects enrolled in the ongoing Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study and c) serum samples from hospitalized patients at the Javits Medical Station (JMS) who participated in the COVID-19 Antibody Prevalence in Military Personnel Deployed to New York (CAMP-NYC) study (30), we describe the utility of three distinct antigen-based MMIAs for COVID-19 serology studies.

Initially, we examined sensitivity differences in detection of SARS-CoV-2 antibodies between widely used antigens: SARS-CoV-2 prefusion stabilized S-2P glycoprotein ectodomain trimer (spike), a monomeric receptor-binding domain (RBD) protein and nucleoprotein (NP).

Additionally, given the high seroprevalence of the seasonal HCoVs (33-35) and evidence of preexisting antibody cross-reactivity with SARS-CoV S glycoprotein (36, 37), we validated
improvements to assay specificity by the concurrent measurement of SARS-CoV-2 and HCoVspecific immunoglobulin G (IgG) in a multiplex approach and report the stimulation of crossreactive antibody responses across ARIC, EPICC and JMS cohorts. Furthermore, we
standardized SARS-CoV-2 and HCoV MMIA SARS-CoV-2 IgG detection in paired venous and
capillary blood specimens collected by serum separator tubes (SST) and dried blood spots
(DBS), respectively.

The objectives of this study were to develop and validate a high throughput antigen based assay which can discriminate SARS-CoV-2 from seasonal human coronavirus (HCoV) infections, as well as SARS-CoV-2 vaccination, including from specimens collected through self-collected DBS specimens which may greatly facilitate the performance of post vaccination serosurveys and vaccine effectiveness studies. This SARS-CoV-2/HCoV MMIA strategy also has the potential to enhance investigations of the interplay of pre-existing seasonal HCoV antibodies on SARS-CoV-2-specific antibody durability, COVID-19 symptom presentation and disease severity, and we present exploratory results here which show that coronavirus serological cross-reactivity is influenced by the severity of SARS-CoV-2 illness.

MATERIALS AND METHODS

Recombinant protein antigens and microsphere coupling

Prefusion stabilized SARS-CoV-2 spike (S) glycoprotein was used in serology testing to capture the full humoral response including all conformation-dependent antibodies. Prefusion stabilized SARS-CoV-2 S-2P glycoprotein ectodomain trimers (spike protein) and SARS-CoV-2 RBD were purchased from LakePharma, Inc. (Hopkinton, MA USA). This SARS-CoV-2 spike protein shares an equivalent ectodomain with the NIH Vaccine Research Center designed SARS-CoV-2 spike protein, and the Mount Sinai SARS-CoV-2 spike protein used in ELISA-

based serology (9, 10, 16, 38, 39).

Design and expression of prefusion stabilized betacoronavirus (β-CoV) HCoV-HKU1, HCoV-OC43, SARS-CoV and MERS-CoV spike proteins have been previously described (37, 38). The alphacoronavirus (α-CoV) HCoV-229E and HCoV-NL63 spike proteins were similarly constructed and prepared (LakePharma, Inc.). The SARS-CoV-2 nucleocapsid protein (NP) was purchased from RayBiotech, Inc. (Peachtree Corners, GA, USA). A mock antigen, consisting of cell culture supernatant from non-transfected HEK cells was collected via centrifugation then filtered through a 0.22 μM PES filter to remove debris. Mock antigen-coupled beads were included in each microtiter well to control for non-specific/artificial antisera binding; samples that react with the mock antigen above an established 3-fold cutoff were retested. Proteins were coupled to carboxylated magnetic MagPlex microspheres (Bio-Rad, Hercules, CA) at a protein to microsphere ratio of 15 μg:100 μL, and antigen-coupled microspheres were resuspended in a final volume of 650 μL following manufacturer's protocol (Bio-Rad) for amine coupling.

Participant enrollment and sera collection

SARS-CoV-2 negative human serum specimens utilized were from sera collected from 2012 – 2018 in the ARIC Natural History Study (IDCRP-045) (32). ARIC sera predate the COVID-19 pandemic and were collected from subjects who had nasopharyngeal swabs tested by nucleic acid amplification methods for virus etiologies of acute respiratory infections; samples collected from individuals with rhinovirus and the seasonal HCoVs, HCoV-OC43, -HKU1, -229E and -NL63 were used (40). In addition, we utilized serum samples collected since the emergence of SARS-CoV-2 under the IDCRP EPICC (IDCRP-085) protocol; a prospective, longitudinal observational cohort study to analyze the natural history of COVID-19 disease. Subjects were enrolled at five hospitals across the continental U.S., including Walter Reed National Military Medical Center (WRNMMC, Bethesda, MD), Brooke Army Medical Center (BAMC, San Antonio, TX), Naval Medical Center San Diego (NMCSD, San Diego, CA),

Madigan Army Medical Center (MAMC, Tacoma, WA) and Fort Belvoir Community Hospital (FBCH, Fort Belvoir, VA). Subjects of all race and gender seeking treatment for acute illness at these military hospitals were offered enrollment into the ARIC, IDCRP-045 and EPICC, IDCRP-085 protocols. EPICC study enrollment included subjects with laboratory-confirmed SARS-CoV-2 infection by nucleic acid amplification test, subjects with compatible illness in whom SARS-CoV-2 infection is initially suspected but PCR confirmed as SARS-CoV-2 negative, and asymptomatic subjects at risk of SARS-CoV-2 due to high risk exposure. Additionally, serum samples from 35 subjects undergoing treatment at JMS under the CAMP-NYC protocol were included in the assessment of assay performance. ARIC (IDCRP-045), EPICC (IDCRP-085) and CAMP-NYC protocols were approved by the Uniformed Services University Institutional Review Board.

Multiplex microsphere-based immunoassay screening procedures

Three antigen-distinct MMIA were established: a) β-CoV MMIA that included SARS-CoV-2 spike and RBD, and SARS-CoV, MERS-CoV, HCoV-HKU1 and HCoV-OC43 spike; b) a SARS-CoV-2 and HCoV MMIA (SARS-2/HCoV) that included SARS-CoV-2, HCoV-HKU1, HCoV-OC43, HCoV-229E and HCoV-NL63 spike; and c) a SARS-CoV-2 spike and NP MMIA (SARS-2 spike/NP) (Table 1).

Serum samples were collected from venipuncture in serum separator tubes, processed and stored at -80 °C in 250 µL aliquots until use. At-home blood collection was performed with Mitra Collection Kits (Neoteryx, Torrance, CA, USA). Microsampler tip dried blood spots (DBS) were placed into deep-96-well microtiter plates containing 400 µL of 1X PBS-T and eluted overnight at 4 °C with agitation, 300 rpm. The duplicate microsampler tip DBS eluents were combined to 800 µL, vortexed, aliquoted to 200 µL and stored at -80 °C until antibody testing. For each 96-well plate, a multiplex master mix of antigen-coupled microspheres was made by diluting 100 µL of each antigen-coupled microsphere working stock into 10 mL (1:100) 1XPBS

without calcium and magnesium (Corning Inc., Corning, NY) (all mentions of PBS refer to solutions without calcium and magnesium), and 100 μ L of this master mix were added to each well so that each well contained 1 μ L (~23 ng) of each antigen-coupled microsphere per well. Wells were washed with 1XPBS + 0.05% Tween20 + 0.02% sodium azide two times. One hundred microliters of each serum sample was added to each well. Serum samples were diluted within a class II type A2 biological safety cabinet (BSC) then subjected to thermal inactivation for 30 min at 60 °C. Human serum samples (1.25 μ L) were diluted 1:400 in PBS and eluted DBS aliquots were diluted 1:10 in PBS, and tested in technical duplicate A and B plates. Controls on each duplicate plate included a PBS blank (wells: A1, B1, G12, H12) and SARS-CoV-2 PCR-confirmed positive (C1, F12) and negative (D1, E12) serum sample. SARS-CoV-2 qualified controls for established expected inter- and intra-plate variations.

Samples were incubated at room temperature for 45 minutes with agitation (900 rpm), and plates were washed three times by an automated plate washer. Secondary antibody (goat anti-human IgG cross-absorbed biotin-conjugated or goat anti-human IgM cross-absorbed biotin-conjugated; Thermo Fisher Scientific, Waltham, MA) was diluted 1:5000 in 1XPBS + 0.05% Tween20 (PBST) and 100 µL of each secondary was added to each well and incubated for 45 minutes with agitation, and plates were washed three times. Streptavidin-phycoerythrin (Bio-Rad) was diluted 1:1000 in PBST and 100 µL was then added to each well and incubated for 30 minutes with agitation, and plates were washed three times. Lastly, 100 µL of PBST was added to each well and plates were resuspended by agitation for 5 minutes. Plates were read on Bio-Plex 200 multiplexing systems (Bio-Rad) with PMT voltage setting to the High RP1 target and 100 bead count requirements. Antibody levels are reported as quantified median fluorescence intensity (MFI). The average MFI of the four PBS-blank wells on each plate were subtracted from the MFI of each sample well and MFI values for samples are reported as the PBS adjusted average from duplicate plates.

Threshold cutoffs for SARS-CoV-2 antibody

To establish threshold cutoffs for SARS-CoV-2 spike protein-specific antibody reactivity, we tested 127 archival acute and convalescent human serum samples from ARIC. Acute and convalescent serum samples were collected within approximately three and twenty-eight days of symptom onset, respectively. We established a cut-off of three standard deviations above the mean (99.7% probability) MFI of archival HCoV PCR-confirmed convalescent serum samples (n= 43) to establish a positivity threshold for detection of SARS-CoV-2 spike protein reactive IgG and IgM antibodies. The remaining 84 archival serum samples were tested against this MFI threshold cutoff for SARS-CoV-2 reactivity. The 127 archival ARIC serum samples were tested in technical duplicates in three independent experiments (β-CoV MMIA) and two independent experiments (SARS-2/HCoV MMIA and SARS-2 spike/NP MMIA) to establish threshold cutoffs and specificity for SARS-CoV-2. A highly reactive HKU1 PCR+ convalescent serum sample to SARS-CoV-2 NP was excluded in the 99.7% threshold sacrificing specificity for sensitivity.

Non-human primate sera

Archived sera were used from rhesus macaques inoculated with a total dose of 2.6x10⁶ TCID50 of SARS-CoV-2 via a combination of intranasal, intratracheal, oral and ocular inoculation routes (41). Serum samples were collected at dpi 0 (baseline) and 21. SARS-CoV-2 IgG antibody seroconversion was determined as a 4-fold increase in MFI compared to the baseline sera collection.

Statistical analysis

Figures were generated and statistical analyses were performed in GraphPad Prism version 7.0. When comparing zoonotic and endemic spike-specific IgG levels, MFI values were log10-transformed, checked for normality and parametric unpaired t-tests were employed to compare EPICC and JMS cohort to ARIC; statistical analysis with one-way ANOVA and Holm-Sidak's multiple comparison were also utilized. When normality was not met, non-parametric

unpaired Mann Whitney tests were performed. The positive predictive value and negative predictive value were calculated with MedCalc statistical software. ROC analysis was conducted using R version 4.0.2.

RESULTS

Generation of threshold cutoffs for SARS-CoV-2 antibodies

Despite low sequence similarity and identity between SARS-CoV-2 spike protein and seasonal HCoV spike proteins, pre-existing antibodies induced by prior infections with seasonal HCoVs are potentially cross-reactive, seemingly driven by conserved epitopes shared by the SARS-CoV-2 S glycoprotein S2 subunit (36, 37, 42). To enhance specificity for SARS-CoV-2 antibody detection, we established antibody positive/negative thresholds with SARS-CoV-2 naïve serum samples from human subjects with PCR-confirmed HCoV infections via the ARIC study (32, 40). First, we examined pre-existing IgG and IgM reactivity to SARS-CoV-2 antigens: spike, RBD and NP. IgG in convalescent sera collected ~28 days after PCR-confirmed HCoV infections were more reactive with SARS-CoV-2 spike and NP than paired acute sera (Fig. 1A-C), suggesting that in a subset of persons recent HCoV-infection induces antibodies that are reactive with SARS-CoV-2 S glycoprotein and NP antigens. In some specific samples IgG in acute serum were more reactive with RBD (Fig. 1B).




Figure 1. Pre-existing cross-reactivity with SARS-CoV-2 antigens informs threshold cutoffs for antibody positivity. Acute and convalescent serum samples from SARS-CoV-2 naïve HCoV PCR-positive subjects were tested in β-CoV (**A-B**) and SARS-CoV-2 spike/NP (**C**) MMIA. SARS-CoV-2 antigens are indicated. Subjects are grouped together based on HCoV PCR confirmation, HCoV-OC43 (n= 16), HCoV-HKU1 (n= 6), HCoV-NL63 (n= 13) and HCoV-229E (n= 10). MFI, median fluorescence intensity; IgG MFI values represent the MEAN of independent experiments performed in technical duplicates.

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

Second, accounting for this pre-existing cross-reactivity, we applied conventional probability distributions three standard deviations above the mean (99.7%) of these ARIC SARS-CoV-2 naïve HCoV-PCR confirmed convalescent sera to generate threshold cutoffs for SARS-CoV-2 positive antibodies (Fig. S1A-C). In addition to 99.7% probability distribution of ARIC sera, receiver operating characteristic (ROC) curve analysis of sera collected from SARS-CoV-2 RT-PCR confirmed subjects enrolled in the ongoing EPICC protocol were applied for spike, RBD and NP reactive IgG thresholds (Fig. S2A-D). ROC analyses identified MFI cutoff values, 4853 and 4144, retaining 100% sensitivity and 100% sensitivity with spike in both β-CoV and SARS-2/HCoV MMIA, respectively. When we applied this ROC curve value as a threshold for SARS-CoV-2 spike reactive IgG, we identified 2/43 (4.7%) serum samples from SARS-CoV-2 naïve ARIC with confirmed recent HCoV-OC43 and HCoV-229E infections above this cutoff (Fig. 1A). Further ROC analyses of antigen-specific IgG reactivity identified optimal MFI cutoff values for RBD of 4622 MFI (sensitivity= 82.7%, specificity= 91.5%) and NP of 6372 MFI (sensitivity= 90.5%, specificity= 100%). Pre-existing antibody reactivity with SARS-CoV-2 RBD and SARS-CoV-NP was further observed in 4/43 (9.3%) and 2/43 (4.7%), respectively, of ARIC serum samples from subjects with recent HCoV infections (Fig. 1B-C). These two distinct approaches to establish SARS-CoV-2 positive antibody threshold cutoffs resulted in very narrow positive/negative indeterminate ranges between the ARIC generated 99.7% threshold cutoff and the EPICC generated ROC curve threshold cutoff for spike, RBD and NP reactive IgG (Table 2).

Validation of multiplex microsphere-based immunoassay strategies

Next, we examined the influence of multiple antigen targets and multiplex composition on the diagnostic specificity and sensitivity of the MMIA strategies. Measurements of MMIA specificities were made using ARIC human serum samples, representing HCoV PCR-positive acute sera, rhinovirus PCR-positive acute/convalescent sera, and acute/convalescent sera from 'no pathogen detected' subjects, and were tested against our established threshold cutoffs. For

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

sensitivity measurements, we utilized sera from SARS-CoV-2 PCR-confirmed human participants in EPICC and CAMP-NYC. Serum samples collected 10 – 73 dpso, median 23.5 dpso (IQR= 9.25) from hospitalized patients (n=35) at the JMS who participated in the crosssectional CAMP-NYC protocol were screened for SARS-CoV-2 IgG antibody reactivity with MMIA strategies. In the β-CoV and SARS-2 S-2P/NP MMIA strategies, serum samples (n= 116) collected 10 – 60 days post-symptom onset (dpso), median 37 dpso (IQR= 13.75), from SARS-CoV-2 PCR-positive outpatient (n= 62) and hospitalized patient (n= 54) participants enrolled in the EPICC protocol were tested for IgG reactivity with SARS-CoV-2 spike and RBD. Using the established threshold cutoffs, SARS-CoV-2 S-2P reactive IgG antibodies were only detected in PCR positive subjects from EPICC and JMS, retaining 100% specificity (Fig. 2A). The respective geometric mean IgG level with 95% confidence intervals (CI) against spike and RBD were 20,542 MFI (18,806-22,440 CI) and 18,271 MFI (16,251-20,542 CI) for EPICC samples (Fig. 2A-B), whereas, the geometric mean IgG level against spike and RBD were 26,829 MFI (25,757-27,945 CI) and 25,869 MFI (24,670-27,126) for JMS samples (Fig. 2A-B). These differences in geometric mean IgG levels are likely a reflection of COVID-19 severity as all JMS participants were hospitalized while outpatients made up a majority of the EPICC participants. Simultaneously utilizing spike and RBD proteins to capture target SARS-CoV-2 reactive IgG, we observed a significant correlation and strong linear relationship (Spearman r value= 0.9748; P= < 0.0001) between antibody binding to spike and RBD (Fig. 2C). SARS-CoV-2 spike reactive IgG antibody detection by β-CoV MMIA was calculated with 95% CI as follows, sensitivity= 99.3% (96.3%-99.9% CI), specificity= 100% (95.7%-100.0% CI). Assuming a US disease prevalence of 5.0%, the the β-CoV MMIA had a positive predictive value (PPV) = 100.0%, and negative predictive value (NPV) = 99.9% (99.8%-100.00% CI) (Table 3). Comparatively, utility of SARS-CoV-2 RBD for IgG detection had a slightly reduced sensitivity= 96.0% (91.5%-98.5%

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

CI), specificity= 96.4% (89.9%-99.2% CI), PPV= 58.6% (31.8%-81.1% CI) and NPV= 99.8% (99.5%-99.9% CI) with a 5.0% prevalence estimate. Utility of a SARS-CoV-2 NP antigen was explored in a SARS-CoV-2 spike/NP MMIA able to simultaneously capture antibodies specific to both S glycoprotein and NP. The respective, geometric mean IgG levels of spike and NP were 25,526 MFI (23,703-27,490 CI) and 20,165 MFI (17,241-23,584 CI) in EPICC, and 30,723 MFI (29,434-32,069) and 30,268 MFI (29,350-31,215 CI) in JMS sera. In the absence of HCoV spike, two ARIC serum samples were cross-reactive with SARS-CoV-2 spike above the positive threshold, and all SARS-CoV-2 PCRconfirmed samples had detectable spike reactive IgG (Fig. 2D). Five ARIC samples were crossreactive with SARS-CoV-2 NP and 11 EPICC subjects developed IgG to spike but not NP (Fig. 2E). Regardless, the correlation between spike and NP was statistically significant (Spearman r value= 0.898; P= < 0.0001) (Fig. 2F). Antigen-specific immune responses to spike and NP have been observed in COVID-19 patients and are associated with disease severity and older age (4, 43, 44). The performance of SARS-CoV-2 NP IgG assay sensitivity= 92.7% (87.3%-96.3% CI), specificity= 94.1% (86.7%-98.0% CI), PPV= 45.0% (25.9%-65.8% CI) and NPV= 99.6% (99.3%-99.8%) (Table 4).




Figure 2. Detection of SARS-CoV-2 reactive serum IgG with S glycoprotein and nucleoprotein antigens. Serum samples were tested in β-CoV MMIA for reactivity with SARS-CoV-2 spike (A) and RBD (B). (C) Correlation analysis of IgG binding to SARS-CoV-2 spike and RBD when tested simultaneously in the β-CoV MMIA. Serum samples were tested in SARS-2 spike/NP MMIA for reactivity with SARS-CoV-2 spike (D) and NP (E). (F) Correlation analysis of IgG binding to SARS-CoV-2 spike and NP when tested simultaneously in the SARS-2 spike/NP MMIA.

SARS-CoV-2 IqG seroconversion has been detected early after exposure and sometimes in parallel with IgM seroconversion (45-47). For SARS-CoV-2 IgM detection, again we applied a ROC analysis threshold, 1445 MFI (Fig. S3A), which was more conservative than the 99.7% probability threshold cutoff, 840 MFI (Fig. S3B). No ARIC sera were reactive above the threshold for SARS-CoV-2 spike protein IqM, and EPICC spike geometric IqM levels were 2612 MFI (1684-2775 95% CI) and JMS spike geometric IgM levels were 11,595 MFI (9438-14,244 95% CI) (Fig. S3C). EPICC sera tested represent a cohort of 62% outpatients, and differences in detectable IqM levels between EPICC and JMS are probably reflections of COVID-19 clinical outcomes that separate cohort. The SARS-CoV-2 spike reactive IgM detection sensitivity was lower than IgG, with performance analysis conducted with serum samples collected ≥ 7 days post-symptom onset, sensitivity= 73.33% (65.51%-80.22% CI), specificity= 100.00% (95.70-100.00%), PPV= 100.00 and NPV= 98.62% (98.20%-98.95%) (Table S1). The temporal window to capture SARS-CoV-2 IgM was shorter than IgG, and as serum samples included in β-CoV MMIA performance analysis ranged from 10 – 60 dpso, lower IgM sensitivity is further driven by outpatient enrollments in the EPICC protocol with an average 28 dpso that were IgG positive, but IgM negative (Table S2).

SARS-2/HCoV spike MMIA

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

The interplay of pre-existing HCoV spike-specific antibodies and COVID-19 outcomes, as well as post vaccine responses, remains a critical question. As such, we also validated a SARS-2/HCoV spike MMIA strategy that can simultaneously measure antibodies to SARS-CoV-2 and all four seasonal HCoVs. To validate this MMIA strategy, we utilized EPICC serum samples (n= 148) from SARS-CoV-2 PCR-positive participants collected 7 – 60 dpso (median= 35, IQR= 23). Again, we detected no SARS-CoV-2 S-2P IgG positives in ARIC sera, and geometric mean IgG levels were 21,487 MFI (19,568-23,584 CI) and 30,871 MFI (30,403-31,346 CI) from EPICC and JMS serum samples, respectively (Fig. 3A). In addition to serum

samples collected at hospitals, the EPICC protocol provides at-home blood collection of capillary blood samples as DBS for longitudinal serology. Of additional importance, we validated paired DBS IgG against serum collected by serum separator tubes (SST) and observed a significant and strong linear correlation of SARS-CoV-2 MFI derived from DBS and SST collected blood specimens (Fig. 3B). Reports have demonstrated anti-S glycoprotein IgG seroconversion between 3 and 14 dpi (41, 48-50), to further assess the MMIA strategy, sensitivity for the SARS-2/HCoV MMIA was measured within an early and narrow range of EPICC and JMS blood specimen collection, 7-28 dpso. SARS-2/HCoV spike MMIA assay performance was, sensitivity= 94.4% (86.4%-98.5% CI), specificity= 100.0% (95.7%-100.0% CI), PPV= 100.0% and NPV= 99.7% (99.3%-99.9% CI) (Table 5). As previously seen with the β-CoV assay, inclusion of HCoV spike improves specificity for SARS-CoV-2; both β-CoV and SARS-2/HCoV MMIAs have near identical upper threshold cutoff values, 4910 MFI and 4774 MFI, thus the inclusion of HCoV-HKU1 and HCoV-OC43 spike led to improvements in specificity.




Figure 3. SARS-2/HCoV MMIA detection of SARS-CoV-2 IgG in blood specimens. (A)

Serum samples were screened with a SARS-2/HCoV spike protein MMIA and reactivity to

SARS-CoV-2 spike is shown; shaded grey bar indicates the threshold cutoff for IgG positivity.

(B) Paired blood specimens (n= 22) collected from capillary blood as a dried blood spot (DBS)

and serum collected by serum separator tubes (SST) were tested with the SARS-2/HCoV spike protein MMIA; SARS-CoV-2 spike reactive IgG MFI is indicated on x- and y-axes.

COVID-19 subject antibody reactivity with zoonotic and endemic coronaviruses Next, we investigated SARS-CoV-2 de novo IgG antibody cross-reactivity with SARS-CoV and MERS-CoV spike proteins. Threshold cutoffs for SARS-CoV and MERS-CoV spike reactive IgG were similarly set with ARIC sera as detailed for SARS-CoV-2 spike (Fig. 4A). An indeterminate range (3840 – 4910 MFI) for positive/negative IgG reactivity was established with SARS-CoV-2, SARS-CoV and MERS-CoV spike protein reactive IgG MFI and 4910 MFI represents the threshold for positivity. We compared levels of SARS-CoV and MERS-CoV reactive IgG in SARS-CoV-2 PCR positive subjects. SARS-CoV and MERS-CoV S glycoprotein share 82% and 50% homology, respectively, with SARS-CoV-2 S glycoprotein (37). A significant level of cross-reactive antibodies to SARS-CoV and MERS-CoV were observed in SARS-CoV-2 PCR positive and IgG positive EPICC and JMS cohort sera, but not SARS-CoV-2 naïve ARIC sera (Fig. 4B). The geometric mean IgG MFI levels of SARS-CoV reactive IgG in EPICC and JMS were 4007 (3422 – 4693 CI) and 9307 (7423 – 11,669 CI), respectively; and the geometric mean IgG MFI levels of MERS-CoV reactive IgG in EPICC and JMS were 4255 (3517 – 5173 CI) and 8307 (6436 – 10,722 CI), respectively.




Figure 4. SARS-CoV and MERS-CoV IgG increases after SARS-CoV-2 infection. (A) 99.7% probability distribution of ARIC HCoV PCR+ convalescent serum samples (n= 43) reactive with SARS-CoV (SARS-1) and MERS-CoV (MERS) spike; a dashed line and solid line indicates the SARS-CoV and MERS-CoV spike protein threshold cutoff values, respectively. (B) Sera from SARS-CoV-2 positive EPICC and JMS cohorts were tested in a β-CoV MMIA for IgG reactivity to SARS-CoV and MERS-CoV spike, a shaded grey line indicates the threshold cutoff for IgG positivity; error bars indicate the geometric mean and 95% confidence intervals; unpaired Mann-Whitney t-tests of EPICC and JMS compared to ARIC, ***** *P*-values= < 0.0001.

In the absence of HCoV naïve human cohort, we turned to SARS-CoV-2 non-human primates (NHP) model to inform the stimulation of HCoV cross-reactive antibodies. NHP had no evidence of de novo IgG reactivity with HCoV-HKU1 and HCoV-OC43 spike proteins after SARS-CoV-2 challenge and seroconversion (Fig. 5A). We extrapolated the 99.7% indeterminate range of SARS-CoV, SARS-CoV-2 and MERS-CoV spike protein reactive IgG as a cutoff for HCoV reactive antibodies (Fig. 4A). We found that IgG reactivity with HCoV spike proteins in the SARS-CoV-2 PCR positive patient serum samples were significantly higher than those in SARS-CoV-2 naïve ARIC cohort. We found significant geometric mean IgG increases of HCoV-OC43, 26,518 (25,920-27,131 CI) and 29,454 (28,759-30,167 CI) in EPICC and JMS cohorts, respectively; HCoV-HKU1 geometric mean IgG levels in EPICC and JMS cohorts were 15,739 (14,693-16,859 CI) and 19,360 (17,027-22,012 CI), respectively (Fig. 5B). Furthermore, we detected a significant increase in IgG-reactive with HCoV-NL63 associated with SARS-CoV-2 infection in EPICC and JMS cohorts; a significant increase in HCoV-229E lgG was detected in JMS sera (Figure 5C).




Figure 5. SARS-CoV-2 infection is associated with rises in HCoV antibody levels.

(A) Serum samples collected 21 dpi from SARS-CoV-2 challenged non-human primates (n= 4) and tested in two independent experiments performed in technical duplicates with a SARS-2/HCoV spike protein MMIA; error bars represent mean±SD. IgG reactivity with seasonal HCoV, -HKU1 and -OC43 (β-CoVs) (B) and -229E and -NL63 (α-CoVs) (C), spike proteins were tested with a SARS-2/HCoV spike MMIA. Error bars indicate the geometric mean and 95% CI, IgG levels were compared by unpaired t-tests with Welch's correction of EPICC and JMS compared to ARIC, **** *P*-values= < 0.0001.

DISCUSSION

In this study, we have demonstrated that use of a multiplex microsphere-based immunoassay (MMIA) built using Luminex xMAP-based technology in which individual microspheres are bound to pre-fusion stabilized S glycoprotein trimers of SARS-CoV-2 and the seasonal endemic HCoVs enables sensitive and specific detection of SARS-CoV-2 IgG antibodies. Our SARS-CoV-2 spike-based MMIA strategies have sensitivities ranging 94 – 99 % as early as 7 – 10 days after symptom onset in PCR-confirmed cases of SARS-CoV-2 infection and 100% specificity for SARS-CoV-2 IgG, comparable with several other EUA serology tests (6). Conserved epitopes present in the prefusion stabilized native-like trimeric S glycoprotein oligomers (spike protein) are the likely major factor in the observed cross reactions between the coronavirus S glycoproteins, affecting specificity for some serology assays. By using HCoV-HKU1 and HCoV-OC43 spike proteins to capture pre-existing antibodies that would be cross-reactive with SARS-CoV-2 spike, the assay had a 100% specificity for SARS-CoV-2 serology. Importantly, the ability to simultaneously capture SARS-CoV-2 spike and NP-specific antibodies within a single assay will facilitate high-throughput approaches for differentiating antibody responses between SARS-CoV-2 natural infections and vaccinations.

The magnitude of the antibody response to SARS-CoV-2 infection has been associated with COVID-19 severity (51). This was apparent in our validation tests as geometric mean IgG levels were consistently elevated in sera from the JMS cohort, comprised of all hospitalized patients, whereas sera from the EPICC cohort had lower geometric mean IgG to SARS-CoV-2 antigens, of which the majority of EPICC study participants were outpatients. Interestingly, geometric mean IgG level, 20,542 MFI (18,806-22,440 CI) to SARS-CoV-2 spike determined by testing with the β-CoV MMIA was lower than the geometric mean IgG levels spike, 25,226 MFI (23,703-27,490 CI) in the SARS-2 spike/NP MMIA. One possibility is that in the β-CoV MMIA, inclusion of spike and RBD which represent overlapping epitopes leads to competition for antibodies, decreasing overall MFI levels to either S glycoprotein antigen individually. The effect

of this binding competition could negatively affect durability studies of longitudinal samples when concentrations of circulating SARS-CoV-2 sera IgG begins to wane. Whereas establishing the SARS-CoV-2 spike protein and NP MMIA will have utility for the future differentiation between antibody responses to SARS-CoV-2 vaccination and natural infection induced antibody responses, with some inherent limitations to sensitivity and specificity.

Of additional importance, the MMIA approach demonstrated *de novo* IgG cross-reactivity with SARS-CoV and MERS-CoV in the SARS-CoV-2 PCR+/IgG+ EPICC and JMS cohorts compared with archival sera (ARIC). The EPICC geometric mean IgG levels reactive with SARS-CoV spike were near the indeterminate range of positivity, suggesting that significant rises in IgG levels after SARS-CoV-2 are driven by a subset of subjects that develop specific B cell repertoires that can be cross-reactive with SARS-CoV. A higher geometric mean IgG level to SARS-CoV and MERS-CoV were detected in JMS sera, which includes all hospitalized patients and suggests that induction of cross-reactivity is associated with COVID-19 severity. Conserved cross-neutralizing epitopes between SARS-CoV and SARS-CoV-2 S glycoproteins have been identified (52, 53), whether SARS-CoV-2 induced *de novo* IgG antibody responses to SARS-CoV and MERS-CoV spike proteins detected with this MMIA strategy are retained after affinity maturation, or are cross-neutralizing requires further investigation. The induction of cross-reactive SARS-CoV, SARS-CoV-2 and MERS-CoV antibodies further demonstrates that shared spike proteins epitopes exist and that rational-vaccine designs may be able to develop pan-zoonotic coronavirus vaccines.

Here, we observed increases in seasonal HCoV spike reactive IgG antibodies in SARS-CoV-2 positive cohort. SARS-CoV-2 has been shown to stimulate OC43 memory B cells through conserved epitopes in the SARS-CoV-2 S glycoprotein S2 subunit and serum samples from subjects with recent HCoV infection contain SARS-CoV-2 cross-reactive but not cross-neutralizing antibodies (54). As *de novo* IgG cross-reactivity with HCoV-HKU1 and HCoV-OC43 spike protein was not observed in SARS-CoV-2 challenged NHPs (Figure 5A), the presence of

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

prior humoral memory to seasonal HCoV appears necessary to drive cross-reactivity. Overall, the OC43 S glycoprotein only shares 30 to 40% amino acid sequence identity/similarity with SARS-CoV-2 S glycoprotein (37). The S1 subunit, wherein resides the RBD, has more sequence variance among OC43 and SARS-CoV-2, in contrast to the S2 subunit heptad repeat regions where amino acid sequence similarity is between 50 to 75%. It would seem unlikely that a SARS-CoV-2 de novo IgG response would result in cross-reactive antibodies that would bind at immunoassay saturation to distantly-related seasonal β-CoVs. However, we did observe increases in HCoV-NL63 spike reactive antibodies EPICC and JMS cohorts, suggestive that SARS-CoV-2 infection and the subsequent heightened inflammatory state can induce a humoral response with enough antibody diversity capable of binding to distantly-related human α-CoVs. It will be important to expand on this observation with larger numbers of subjects in different age groups to evaluate the extent of SARS-CoV-2 stimulated seasonal HCoV memory responses. Other, preliminary evidence has estimated a negative relationship between HKU1 and OC43 back-boosted responses and the generation of SARS-CoV-2 neutralizing antibodies (55), implying that in some subjects OC43 immune imprinting may have similar effects akin to immunological imprinting, antigenic epitope masking and/or original antigenic sin (56, 57). Whether HCoV immune imprinting has any association with clinical outcomes or SARS-CoV-2 antibody longevity requires further investigation. Back-boosting stimulation of a cross-reactive memory response might also explain cases of synchronous SARS-CoV-2 IgM and IgG seroconversion and IgG seroconversion prior to IgM (58). To our knowledge there is no evidence that HCoV-induced antibodies promote clinical protection in SARS-CoV-2 infected individuals. The vast majority of the SARS-CoV-2 confirmed participants in these studies had high levels of HCoV-OC43 IgG; however, they were also seeking treatment for mild to moderate/severe COVID-19 which requires further investigation. Larger, prospective, longitudinal observational studies in which serum samples are obtained before infection may ultimately be required to definitively determine if HCoV-induced antibodies confer any protection

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

against COVID-19 and if the presence of HCoV memory affects the longevity and development of a protective SARS-CoV-2 humoral response. **DECLARATIONS** These research protocols, IDCRP-085, IDCRP-045 and CAMP-NYC, were approved by the USU IRB. The data that support the findings of this study are available from the corresponding author(s upon reasonable request. **ETHICS STATEMENT** The referenced human subjects protocols (IDCRP-045, IDCRP-085, and CAMP-NYC) were approved by the Uniformed Services University Institutional Review Board and participating sites. All subjects provided written or verbal informed consent using approved documents and procedures; the consent forms include clauses allowing use of specimens for investigations including those conducted in this study. **CONFLICT OF INTEREST** None of the authors have any conflicts of interest of relevance to disclose. **DISCLAIMER** The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions, or policies of the Uniformed Services University (USU), the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), National Institutes of Health or the Department of Health and Human Services, Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the US Department of Defense (DoD), the Departments of the Air Force, Army or

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

Navy, or the U.S. Government. Mention of trade names, commercial products, or organization does not imply endorsement by the U.S. Government. A number of the co-authors are military service members (or employees of the U.S. Government). This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. **FUNDING** This project has been funded by the Defense Health Program, U.S. DoD, under award HU0001190002 and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072. This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E. VJM and EdW are supported by the Intramural Research Program of the National Institutes of Allergy and Infectious Diseases. **ACKNOWLEDGEMENTS** We thank Kelly Snead, Vanessa Wall, John-Paul Denson, Simon Messing, and William Gillette (Protein Expression Lab, FNCLR) for excellent technical assistance. We also thank Kathleen Pratt (Department of Medicine, USUHS) for assistance with CAMP-NYC sample acquisition.

REFERENCES

683

- 684 1. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al 685 Khalili S, Simonsen L. 2020. Comparing SARS-CoV-2 with SARS-CoV and influenza 686 pandemics. Lancet Infect Dis 20:e238-e244.
- Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J,
 Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T. 2020. Genome Composition and
 Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host
 Microbe 27:325-328.
- Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. 2020. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. bioRxiv doi:10.1101/2020.11.15.383323.
- Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, Hunter M, Wang H, Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otrelo-Cardoso AR, Pham TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL, Wang TT, Narasimhan B, Gombar S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA, Boyd SD. 2020. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 5.
- Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, Goldgof
 GM, Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW, Bern C, Wu AHB.
 2020. Magnitude and Kinetics of Anti–Severe Acute Respiratory Syndrome Coronavirus
 Antibody Responses and Their Relationship to Disease Severity. Clinical Infectious
 Diseases 72:301-308.
- 707 6. F.D.A US. (2021, January 8) EUA authorized serology test performance.
- 708 7. Hartenian È, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. 2020. The molecular virology of Coronaviruses. J Biol Chem doi:10.1074/jbc.REV120.013930.
- Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA,
 Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR,
 Chappell JD, Graham BS, Ward AB, McLellan JS. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A
 114:E7348-e7357.
- 715 9. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260-1263.
- Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M,
 Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G,
 Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska
 K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. 2020. A serological assay to detect
 SARS-CoV-2 seroconversion in humans. Nat Med 26:1033-1036.
- 11. Esposito D, Mehalko J, Drew M, Snead K, Wall V, Taylor T, Frank P, Denson JP, Hong
 M, Gulten G, Sadtler K, Messing S, Gillette W. 2020. Optimizing high-yield production of
 SARS-CoV-2 soluble spike trimers for serology assays. Protein Expr Purif 174:105686.
- 727 12. Kalish H, Klumpp-Thomas C, Hunsberger S, Baus HA, Fay MP, Siripong N, Wang J,
 728 Hicks J, Mehalko J, Travers J, Drew M, Pauly K, Spathies J, Ngo T, Adusei KM,
 729 Karkanitsa M, Croker JA, Li Y, Graubard BI, Czajkowski L, Belliveau O, Chairez C,
- 730 Snead K, Frank P, Shunmugavel A, Han A, Giurgea LT, Rosas LA, Bean R, Athota R,
- 731 Cervantes-Medina A, Gouzoulis M, Heffelfinger B, Valenti S, Caldararo R, Kolberg MM,
- Kelly A, Simon R, Shafiq S, Wall V, Reed S, Ford EW, Lokwani R, Denson JP, Messing

- 733 S, Michael SG, Gillette W, Kimberly RP, Reis SE, Hall MD, et al. 2021. Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States. medRxiv doi:10.1101/2021.01.27.21250570.
- Klumpp-Thomas C, Kalish H, Drew M, Hunsberger S, Snead K, Fay MP, Mehalko J,
 Shunmugavel A, Wall V, Frank P, Denson JP, Hong M, Gulten G, Messing S, Hicks J,
 Michael S, Gillette W, Hall MD, Memoli MJ, Esposito D, Sadtler K. 2021. Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and athome blood sampling. Nat Commun 12:113.
- Okba NMA, Müller M, Li W, Wang C, GeurtsvanKessel C, Corman V, Lamers M,
 Sikkema R, de Bruin E, Chandler F, Yazdanpanah Y, Le Hingrat Q, Descamps D,
 Houhou-Fidouh N, Reusken CBEM, Bosch B-J, Drosten C, Koopmans MPG, Haagmans B. 2020. Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody
 Responses in Coronavirus Disease Patients. Emerging Infectious Disease journal
 26:1478.
- 747 15. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ,
 748 Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael
 749 N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz
 750 J, Baric RS, de Silva AM. 2020. The receptor-binding domain of the viral spike protein is
 751 an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
 752 Science Immunology 5:eabc8413.
- Klumpp-Thomas C, Kalish H, Drew M, Hunsberger S, Snead K, Fay MP, Mehalko J,
 Shunmugavel A, Wall V, Frank P, Denson JP, Hong M, Gulten G, Messing S, Hicks J,
 Michael S, Gillette W, Hall MD, Memoli M, Esposito D, Sadtler K. 2020. Standardization
 of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic
 using clinical and at-home blood sampling. medRxiv doi:10.1101/2020.05.21.20109280.
- 758
 759
 760
 761
 Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y, Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv doi:10.1101/2020.03.30.20047365:2020.03.30.20047365.
- Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR,
 Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. 2020. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 38:1073-1078.
- Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, Widdowson M-A,
 Mortgat L, Duysburgh E, Desombere I, Jansens H, Van Esbroeck M, Ariën KK. 2021.
 Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody
 detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
 Journal of Virological Methods 288:114025.
- Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, Parker
 MM, John Leung SY, Morne JE, Greene D, Holtgrave DR, Hoefer D, Kumar J, Udo T,
 Hutton B, Zucker HA. 2020. Cumulative incidence and diagnosis of SARS-CoV-2
 infection in New York. Ann Epidemiol 48:23-29.e4.
- Norman M, Gilboa T, Ogata AF, Maley AM, Cohen L, Busch EL, Lazarovits R, Mao C-P,
 Cai Y, Zhang J, Feldman JE, Hauser BM, Caradonna TM, Chen B, Schmidt AG, Alter G,
 Charles RC, Ryan ET, Walt DR. 2020. Ultrasensitive high-resolution profiling of early
 seroconversion in patients with COVID-19. Nature Biomedical Engineering
 doi:10.1038/s41551-020-00611-x.
- 780
 781
 781
 782
 Bray RA, Lee JH, Brescia P, Kumar D, Nong T, Shih R, Woodle ES, Maltzman JS,
 Gebel HM. 2021. Development and Validation of a Multiplex, Bead-based Assay to
 Detect Antibodies Directed Against SARS-CoV-2 Proteins. Transplantation 105:79-89.

- Drouot L, Hantz S, Jouen F, Velay A, Lamia B, Veber B, Sibilia J, Lotellier M, Candon S,
 Alain S, Fafi-Kremer S, Boyer O. 2020. Evaluation of Humoral Immunity to SARS-CoV-2:
 Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay. Front
 Microbiol 11:603931.
- Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M. 2017. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus. J Clin Microbiol 55:165-176.
- 791 25. Powell RL, Ouellette I, Lindsay RW, Parks CL, King CR, McDermott AB, Morrow G.
 792 2013. A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV 793 Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from
 794 Rhesus Macagues Infected with SIVmac239. Biores Open Access 2:171-8.
- 795
 796
 797
 Satterly NG, Voorhees MA, Ames AD, Schoepp RJ. 2017. Comparison of MagPix
 Assays and Enzyme-Linked Immunosorbent Assay for Detection of Hemorrhagic Fever
 Viruses. J Clin Microbiol 55:68-78.
- 798 27. Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E, Beer S, Beveridge A, Bibi 799 S, Blackwell L, Borak M, Bown A, Brooks T, Burgess-Brown NA, Camara S, Catton M, 800 Chau KK, Christott T, Clutterbuck E, Coker J, Cornall RJ, Cox S, Crawford-Jones D, 801 Crook DW, D'Arcangelo S, Dejnirattsai W, Dequaire JMM, Dimitriadis S, Dingle KE, 802 Doherty G, Dold C, Dong T, Dunachie SJ, Ebner D, Emmenegger M, Espinosa A, Eyre 803 DW, Fairhead R, Fassih S, Feehily C, Felle S, Fernandez-Cid A, Fernandez Mendoza 804 M, Foord TH, Fordwoh T, Fox McKee D, Frater J, Gallardo Sanchez V, Gent N, 805 Georgiou D, Groves CJ, et al. 2020. Performance characteristics of five immunoassays 806 for SARS-CoV-2: a head-to-head benchmark comparison. The Lancet Infectious 807 Diseases 20:1390-1400.
- 808 28. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384:403-416.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Jr., Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603-2615.
- S19 30. Clifton GT, Pati R, Krammer F, Laing ED, Broder CC, Mendu DR, Chen HW, Sugiharto VA, Simons MP, Kang AD, Stadlbauer D, Pratt KC, Bandera BC, Fritz DK, Millar EV, Burgess TH, Chung KK. 2021. SARS-CoV-2 infection risk among active duty military members deployed to a New York City field hospital in support of the COVID-19 pandemic response. MMWR *in press*
- Lalani T, Lee TK, Laing ED, Ritter A, Cooper E, Lee M, Baker M, Baldino T, McAdoo T,
 Phogat S, Samuels E, Nguyen H, Broder CC, Epsi N, Richard SA, Warkentien TE, Millar
 EV, Burgess T, Kronmann KC. 2021. SARS-CoV-2 Infections and Serologic Responses
 Among Military Personnel Deployed on the USNS COMFORT to New York City During
 the COVID-19 Pandemic. Open Forum Infect Dis 8:ofaa654.
- Coles C, Millar EV, Burgess T, Ottolini MG. 2019. The Acute Respiratory Infection
 Consortium: A Multi-Site, Multi-Disciplinary Clinical Research Network in the Department of Defense. Mil Med 184:44-50.

- 832 33. Kozak R, Prost K, Yip L, Williams V, Leis JA, Mubareka S. 2020. Severity of coronavirus respiratory tract infections in adults admitted to acute care in Toronto, Ontario. J Clin Virol 126:104338.
- Nickbakhsh S, Thorburn F, B VONW, Mc MJ, Gunson RN, Murcia PR. 2016. Extensive multiplex PCR diagnostics reveal new insights into the epidemiology of viral respiratory infections. Epidemiol Infect 144:2064-76.
- Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. 2016.
 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends
 Microbiol 24:490-502.
- 841 36. Freeman B, Lester S, Mills L, Rasheed MAU, Moye S, Abiona O, Hutchinson GB,
 842 Morales-Betoulle M, Krapinunaya I, Gibbons A, Chiang C-F, Cannon D, Klena J,
 843 Johnson JA, Owen SM, Graham BS, Corbett KS, Thornburg NJ. 2020. Validation of a
 844 SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance.
 845 bioRxiv: the preprint server for biology
 846 doi:10.1101/2020.04.24.057323:2020.04.24.057323.
- Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, Snead K,
 Drew M, Corbett K, Graham B, Hall MD, Esposito D, Sadtler K. 2020. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. medRxiv doi:10.1101/2020.06.22.20137695.
- 851 38. Esposito D, Mehalko J, Drew M, Snead K, Wall V, Taylor T, Frank P, Denson JP, Hong 852 M, Gulten G, Sadtler K, Messing S, Gillette W. 2020. Optimizing high-yield production of 853 SARS-CoV-2 soluble spike trimers for serology assays. bioRxiv 854 doi:10.1101/2020.05.27.120204.
- 855
 856
 856
 857
 858
 858
 Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS,
 859
 850
 851
 Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep
 858
 859
 850
 850
 851
 851
 851
 851
 852
 853
 854
 855
 856
 857
 857
 857
 858
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 850
 <
- 859 40. Bouvier M, Chen WJ, Arnold JC, Fairchok MP, Danaher PJ, Lalani T, Malone L, Mor D,
 860 Ridoré M, Burgess TH, Millar EV. 2018. Species-specific clinical characteristics of
 861 human coronavirus infection among otherwise healthy adolescents and adults. Influenza
 862 Other Respir Viruses 12:299-303.
- Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Pérez-Pérez L, Schulz J,
 Meade-White K, Okumura A, Callison J, Brumbaugh B, Avanzato VA, Rosenke R,
 Hanley PW, Saturday G, Scott D, Fischer ER, de Wit E. 2020. Respiratory disease in
 rhesus macaques inoculated with SARS-CoV-2. Nature doi:10.1038/s41586-020-2324 7.
- 868 42. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, 869 Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson P, 870 Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, Shin 871 GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR, 872 Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, Ciurtin C, 873 Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin 874 SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. 2020. Preexisting and de novo 875 humoral immunity to SARS-CoV-2 in humans. Science 370:1339-1343.
- Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin W-H, Wontakal S, Szabo PA, Wells SB, Dogra P, Gray J, Idzikowski E, Stelitano D, Bovier FT, Davis-Porada J, Matsumoto R, Poon MML, Chait M, Mathieu C, Horvat B, Decimo D, Hudson KE, Zotti FD, Bitan ZC, La Carpia F, Ferrara SA, Mace E, Milner J, Moscona A, Hod E, Porotto M, Farber DL. 2021. Distinct antibody responses to SARS-CoV-2 in children and adults across the

881 COVID-19 clinical spectrum. Nature Immunology 22:25-31.

- Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL,
 Wolf C, Yu J, Shuey K, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Suscovich
 TJ, Linde C, Cai Y, Barouch D, Ryan ET, Charles RC, Lauffenburger D, Chu H, Alter G.
 2020. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity
 53:524-532.e4.
- Liu L, Liu W, Zheng Y, Jiang X, Kou G, Ding J, Wang Q, Huang Q, Ding Y, Ni W, Wu W,
 Tang S, Tan L, Hu Z, Xu W, Zhang Y, Zhang B, Tang Z, Zhang X, Li H, Rao Z, Jiang H,
 Ren X, Wang S, Zheng S. 2020. A preliminary study on serological assay for severe
 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital
 patients. Microbes and infection 22:206-211.
- 46. Lou B, Li T-D, Zheng S-F, Su Y-Y, Li Z-Y, Liu W, Yu F, Ge S-X, Zou Q-D, Yuan Q, Lin S,
 Hong C-M, Yao X-Y, Zhang X-J, Wu D-H, Zhou G-L, Hou W-H, Li T-T, Zhang Y-L,
 Zhang S-Y, Fan J, Zhang J, Xia N-S, Chen Y. 2020. Serology characteristics of SARSCoV-2 infection after exposure and post-symptom onset. European Respiratory Journal
 56:2000763.
- 47. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao
 48. Y, Zhang L, Han L, Dang S, Xu Y, Yang Q-W, Xu S-Y, Zhu H-D, Xu Y-C, Jin Q, Sharma
 48. L, Wang L, Wang J. 2020. Profiling Early Humoral Response to Diagnose Novel
 47. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao
 48. Y, Zhang L, Han L, Dang S, Xu Y, Yang Q-W, Xu S-Y, Zhu H-D, Xu Y-C, Jin Q, Sharma
 49. L, Wang L, Wang J. 2020. Profiling Early Humoral Response to Diagnose Novel
 49. Coronavirus Disease (COVID-19). Clinical Infectious Diseases 71:778-785.
- 901 48. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F,
 902 Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao
 903 L, Liu X, Wei Q, Qin C. 2020. Primary exposure to SARS-CoV-2 protects against
 904 reinfection in rhesus macaques. Science 369:818-823.
- 49. Lu S, Zhao Y, Yu W, Yang Y, Gao J, Wang J, Kuang D, Yang M, Yang J, Ma C, Xu J,
 906 Qian X, Li H, Zhao S, Li J, Wang H, Long H, Zhou J, Luo F, Ding K, Wu D, Zhang Y,
 907 Dong Y, Liu Y, Zheng Y, Lin X, Jiao L, Zheng H, Dai Q, Sun Q, Hu Y, Ke C, Liu H, Peng
 908 X. 2020. Comparison of nonhuman primates identified the suitable model for COVID-19.
 909 Signal Transduct Target Ther 5:157.
- Shan C, Yao YF, Yang XL, Zhou YW, Gao G, Peng Y, Yang L, Hu X, Xiong J, Jiang RD,
 Zhang HJ, Gao XX, Peng C, Min J, Chen Y, Si HR, Wu J, Zhou P, Wang YY, Wei HP,
 Pang W, Hu ZF, Lv LB, Zheng YT, Shi ZL, Yuan ZM. 2020. Infection with novel
 coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Res 30:670-677.
- 915 51. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, 916 Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Ollmann Saphire E, Smith DM, 918 Sette A, Crotty S. 2020. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 183:996-1012.e19.
- 920 52. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-921 Fregni C, Pinto D, Rosen LE, Bowen JE, Acton OJ, Jaconi S, Guarino B, Minola A, Zatta 922 F, Sprugasci N, Bassi J, Peter A, De Marco A, Nix JC, Mele F, Jovic S, Rodriguez BF, 923 Gupta SV, Jin F, Piumatti G, Lo Presti G, Pellanda AF, Biggiogero M, Tarkowski M, 924 Pizzuto MS, Cameroni E, Havenar-Daughton C, Smithey M, Hong D, Lepori V, Albanese 925 E, Ceschi A, Bernasconi E, Elzi L, Ferrari P, Garzoni C, Riva A, Snell G, Sallusto F, Fink 926 K, Virgin HW, Lanzavecchia A, Corti D, Veesler D. 2020. Mapping Neutralizing and 927 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by 928 Structure-Guided High-Resolution Serology. Cell 183:1024-1042.e21.
- Jang J, Gu C, Zhou B, Zhang C, Yang Y, Xu S, Bai L, Zhang R, Deng Q, Yuan Z, Tang H, Qu D, Lavillette D, Xie Y, Huang Z. 2020. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. Cell Discov 6:61.

- 933 54. Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatziioannou T, Bieniasz P.
 934 2020. Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from
 935 individuals with recent seasonal coronavirus infection. Clin Infect Dis
 936 doi:10.1093/cid/ciaa1803.
- 937 55. Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, Escalera A, Amanat
 938 F, Jiang K, Krammer F, Carratala J, García-Sastre A. 2020. Antibody Immunological
 939 Imprinting on COVID-19 Patients. medRxiv
 940 doi:10.1101/2020.10.14.20212662:2020.10.14.20212662.
- 56. Zarnitsyna VI, Ellebedy AH, Davis C, Jacob J, Ahmed R, Antia R. 2015. Masking of
 antigenic epitopes by antibodies shapes the humoral immune response to influenza.
 Philos Trans R Soc Lond B Biol Sci 370.
- 944 57. Kelvin AA, Zambon M. 2019. Influenza imprinting in childhood and the influence on vaccine response later in life. Euro Surveill 24.

58. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K,
 247 Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. 2020. Clinical and
 248 immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26:1200-1204.

TABLES

Table 1. Antigen composition of each MMIA

| MMIA variation | Virus | Antigen |
|-----------------|------------|---------|
| β-CoV | SARS-CoV-2 | spike |
| | SARS-COV-Z | RBD |
| | SARS-CoV | spike |
| | MERS-CoV | spike |
| | HCoV-HKU1 | spike |
| | HCoV-OC43 | spike |
| SARS-2/HCoV | SARS-CoV-2 | spike |
| | HCoV-HKU1 | spike |
| | HCoV-OC43 | spike |
| | HCoV-229E | spike |
| | HCoV-NL63 | spike |
| SARS-2 spike/NP | SARS-CoV-2 | spike |
| | SANS-COV-Z | NP |

Table 2. MFI threshold cutoffs for SARS-CoV-2 positive IaG

| MMIA variation | antigen | 99.7% (ARIC) | ROC (EPICC) |
|-----------------|---------|--------------|-------------|
| β-CoV | spike | 4910 | 4853 |
| | RBD | 4666 | 4622 |
| SARS-2/HCoV | spike | 4774 | 4144 |
| SARS-2 spike/NP | NP | 6649 | 6372 |

Table 3. β-CoV MMIA performance

| | | | SARS-CoV-2 PCR Status/Archival Sera | | | |
|-----------------------|--|--|---|--|--|--|
| | Positive ¹ | Negative | Total | | | |
| Positive | 149 | 0 | 149 | | | |
| Negative ² | 1 | 84 | 85 | | | |
| Total | 150 | 84 | 234 | | | |
| Sensitivity 99.33 | | | | | | |
| Specificity 100% | | | | | | |
| | | | | | | |
| | Positive | Negative | Total | | | |
| Positive | 144 | 3 | 147 | | | |
| Negative | 6 | 81 | 87 | | | |
| Total | 150 | 84 | 234 | | | |
| Sensitivity | 96.00% | | | | | |
| Specificity | 96.43% | | | | | |
| | Negative ² Total Sensitivity Specificity Positive Negative Total Sensitivity | Positive 149 Negative² 1 Total 150 Sensitivity 99.33 Specificity Positive Positive Negative 6 Total 150 Sensitivity 96.00% | Positive 149 0 Negative² 1 84 Total 150 84 Sensitivity 99.33 100% Specificity Negative Negative Positive Negative 81 Total 150 84 Sensitivity 96.00% Specificity 96.43% | | | |

¹Performance analysis included serum samples from n= 116 PCR positive subjects including 62 outpatients, 54 hospitalized subjects and 34 JMS hospitalized subjects

²Negative samples were drawn from the pre-2019 ARIC sera collection

Table 4. SARS-2 spike/NP MMIA performance

979

980 981 982

983

984985

| | SARS-CoV-2 PCR Status/Archival Sera | | | |
|---------------------------------------|-------------------------------------|----------|----------|-------|
| SARS-CoV-2 NP IgG Antibody Test | | Positive | Negative | Total |
| | Positive | 139 | 5 | 144 |
| | Negative | 11 | 79 | 90 |
| | Total | 150 | 84 | 234 |
| | Sensitivity | 92.7% | | |
| | Specificity | | 94.1% | |

Table 5. SARS-2/HCoV MMIA performance

| | SARS-CoV-2 PCR Status/Archival Sera | | | |
|--|-------------------------------------|----------|----------|-------|
| SARS-CoV-2 spike IgG Antibody Test | | Positive | Negative | Total |
| | Positive | 68 | 0 | 68 |
| | Negative | 4 | 84 | 88 |
| | Total | 72 | 84 | 156 |
| | Sensitivity | 94.4% | | |
| | Specificity | 100% | | |

¹IgG antibody test included serum samples collected 7-28 days post-onset from PCR positive EPICC and JMS participants.